LXRX vs NVO
LXRX: An early-stage commercial biopharmaceutical company with a gene-discovery platform advancing cardiovascular and metabolic therapies, headlined by commercialized INPEFA and Phase 3 hypertrophic cardiomyopathy candidate sotagliflozin. NVO: A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative medicines and expanded access.
Side-by-side fundamentals
| Metric | LXRX | NVO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.25 | $48.19 | |
| Market cap as of 2026-07-23 | $1.0B | $219.8B | |
| P/E as of 2026-07-23 | n/a | 11.78 | |
| PEG as of 2026-07-23 | n/a | 16.16 | |
| Net margin as of 2026-07-23 | -37.5% | +37.2% | NVO higher |
| Gross margin as of 2026-07-23 | +99.5% | +81.8% | LXRX higher |
| Operating margin as of 2026-07-23 | -34.8% | +45.3% | NVO higher |
| ROE as of 2026-07-23 | -18.6% | +66.4% | NVO higher |
| ROA as of 2026-07-23 | -11.8% | +23.3% | NVO higher |
| Debt / equity as of 2026-07-23 | 0.24 | 0.72 | LXRX lower |
| Revenue growth (YoY) as of 2026-07-23 | +123.1% | +8.1% | LXRX higher |
| Revenue CAGR (3y) SEC XBRL | +610.3% | n/a | |
| Dividend yield as of 2026-07-23 | n/a | +3.7% | |
| Beta as of 2026-07-23 | 1.03 | 1.85 | |
| 1-year return as of 2026-07-22 close | +87.5% | -23.8% | LXRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.